1. **For the 4 months from May to August 2022, how many patients received the following anti-VEGF treatments for any eye condition: Aflibercept**

   Bevacizumab
   Brolucizumab
   Dexamethasone
   Faricimab
   Ranibizumab – Lucentis
   Ranibizumab – Ongavia

   Please find below the quantities dispensed from the Health Board pharmacies for the period July – October 2022 Ophthalmology.

   Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

Type	Quantity
AFLIBERCEPT (EYLEA) 3.6 mg in 0.09mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	4077
DEXAMETHASONE (BASE) 3.3 mg in 1mL Injection 10 Ampoule Pack	18
DEXAMETHASONE 700 micrograms Implant 1 Implant Pack	3
RANIBIZUMAB (LUCENTIS) 1.65 mg in 0.165mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	765
RANIBIZUMAB (ONGAVIA) 2.3 mg in 0.23mL Intravitreal Injection 1 Vial Pack	30

2. **For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.**
   Aflibercept
   Bevacizumab
   Brolucizumab
   Dexamethasone
   Faricimab
   Ranibizumab – Lucentis
   Ranibizumab – Ongavia

The Health Board is not able to provide this information as it is not held centrally. In order to determine this the Health Board would have to review every patient record. Therefore, in order to comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

3. **How many patients have you treated in the last 12 months with the following drugs?**
    Genotropin
    Humatrope
    Norditropin
    Nutropin
    Omnitrope
    Saizen
    Zomacton
    Any other Somatropin (please specify)
    Nil